Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy

Italian Heart Journal

Volumn 1, Issue 3, 2000, Pages 200-206

  Airoldi, F ^a   Di Mario, C ^a   Catanoso, A ^a   Dharmadhikari, A ^a   Tzifos, V ^a   Anzuini, A ^a   Carlino, M ^a   Briguori, C ^a   Montorfano, M ^a   Vaghetti, M ^a   Tolaro, S ^a   Colombo, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Hypertrophic cardiomyopathy; Intraventricular gradient; Septal alcoholization

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HEPARIN; ISOPRENALINE; VERAPAMIL;

ADULT; AGED; ARTICLE; BALLOON CATHETER; CARDIOMYOPATHY; CATHETER ABLATION; CLINICAL ARTICLE; CLINICAL TRIAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; CREATINE KINASE; ELECTROCARDIOGRAPHY; ETHANOL; FEMALE; HEART CATHETERIZATION; HEART SEPTUM; HUMAN; MALE; MIDDLE AGE; PROSPECTIVE STUDIES;

EID: 0033830711     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. The management of hypertrophic cardiomyopathy
2. Perspectives of role of new treatment strategies in hypertrophic obstructive cardiomyopathy
3. Prognosis in hypertrophic cardiomyopathy: A retrospective study
4. Hypertrophic cardiomyopathy. Clinical spectrum and treatment
5. Effects of disopyramide on left ventricular diastolic function in hypertrophic cardiomyopathy
6. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy
7. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy
8. DDD pacing in hypertrophic cardiomyopathy: A multicenter clinical experience
9. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy
10. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
11. Long-term clinical and echocardiographic follow-up after surgical correction of obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular apparatus
12. Long-term results of left ventricular myotomy and myectomy for obstructive cardiomyopathy
13. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy
14. Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and diastolic function
15. Effects of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: Acute Doppler echocardiographic and catheterization hemodynamic study
16. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy
17. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY)
18. Alcoholization of the interventricular septum (Sigwart procedure) for treatment of hypertrophic cardiomyopathy
19. Non surgical septal reduction for hypertrophic obstructive cardiomyopathy. Outcomes in the first series of patients
20. Percutaneous transluminal septal myocardial ablation in hypertrophic cardiomyopathy: Acute results and 3-month follow-up in 25 patients
21. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy
22. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic cardiomyopathy
23. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Results with respect to intraprocedural myocardial contrast echocardiography
24. Role of myocardial contrast echocardiography during non surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy
25. Changes in the left ventricular outflow tract after transcoronary ablation of the septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilisation and perfusion
26. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatients population
27. Hypertrophic cardiomyopathy in Tuscany: Clinical course and outcome in an unselected regional population